Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market ...

(Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed a patent infringement lawsuit against Cleerly, Inc. in the United States ...

Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed ...

A study, conducted by GB Pant Hospital, found that 80% of patients who suffered a first heart attack were not identified as ...

In a field that prides itself on evidence-based medicine, we have allowed a remarkable degree of variation under the banner ...

The Northwestern Medicine Grayslake Outpatient Center continues to evolve as one of Lake County’s most comprehensive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NEW ORLEANS — In a global cohort of people from 15 ...

A simpler alternative to open heart surgery is gaining popularity, but some find ​their new valves don’t last as long as they ...

Emerging evidence may help reshape antiplatelet and lipid strategies for the management of coronary artery disease.

PCI for coronary chronic total occlusion significantly improves angina symptom scores compared with placebo in patients with stable angina.

NEW ORLEANS, LA—Olezarsen (Ionis Pharmaceuticals), an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA), does not reduce noncalcified coronary plaque volume despite lowering ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated ...